Research Triangle Park, NC, March 5, 2020 – Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that the U.S. Patent and Trademark Office will issue U.S. Patent 10,596,190 […]
Read More… from FENNEC ANNOUNCES ISSUANCE OF U.S. PATENT FOR USE OF PEDMARK™
Potential First Product in Europe for the Prevention of Cisplatin-Induced Hearing Loss in Children Research Triangle Park, NC, Feb. 28, 2020 – Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the company’s Marketing Authorization Application (MAA) for its investigational drug, sodium thiosulfate (unique formulation) for infusion (tradename to be […]
NDA (New Drug Application) and Marketing Authorization Application (MAA) completed in February 2020 Commercial readiness activities in US underway for potential launch of PEDMARKTM, is approved, in the second half of 2020 Solid financial position with $13.7 million and no debt and the option to access $12.5 million in debt financing upon FDA approval of […]
Read More… from FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES FISCAL YEAR 2019 FINANCIAL RESULTS
PEDMARKTM[1] is Being Developed for Prevention of Cisplatin-Induced Hearing Loss in Children Research Triangle Park, NC, Feb. 11, 2020 – Fennec Pharmaceuticals Inc. (Nasdaq:FENC; TSX: FRX), a specialty pharmaceutical company, today announced it has completed its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for PEDMARKTM (a unique […]
NDA (New Drug Application) for PEDMARKTM to be completed in early 2020 Strong financial position with $15.2 million in cash and no debt Research Triangle Park, NC, November 12, 2019 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for […]
Read More… from FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS
Research Triangle Park, NC, October 2, 2019 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that Rosty Raykov, Chief Executive Officer of Fennec, will present at the Cantor […]
Read More… from FENNEC TO PRESENT AT THE 2019 CANTOR GLOBAL HEALTHCARE CONFERENCE ON OCTOBER 4, 2019
Research Triangle Park, NC, September 24, 2019 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that it has appointed Jodi A. Cook, PhD to its board of directors. […]
Read More… from FENNEC APPOINTS JODI A. COOK, PhD TO ITS BOARD OF DIRECTORS
Seasoned commercial leader to lead the anticipated launch of PEDMARKTM Research Triangle Park, NC, September 9, 2019 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that it has […]
Read More… from FENNEC APPOINTS SHUBH GOEL AS CHIEF COMMERCIAL OFFICER
Anticipate PEDMARK™ New Drug Application (NDA) completion by early 2020 Strong financial position with $17.5 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., Aug. 09, 2019 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate (STS)) for the prevention […]
Read More… from Fennec Provides Business Update and Announces Second Quarter 2019 Financial Results
Research Triangle Park, NC — (Marketwired) – June 18, 2019 – Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated May 14, 2019 (the “Circular”) for the Annual General and Special Meeting of Shareholders were elected as directors of the Company at the Annual General […]